Search PubMed⌕ Search

Biomedical subjects

G Spitzer

Publications and source records attributed to G Spitzer.

224 records · Page 13Linked to original sources
PubMedDate not supplied

Rescue by peripheral blood mononuclear cells in dogs from bone marrow failure after total-body irradiation.

In order to determine the minimum dose of buffy coat cells necessary to achieve hematopoietic rescue following supralethal irradiation, mongrel dogs under general anesthesia were subjected to leukacytapheresis using three different techniques of cell separation. The buffy coats were frozen with dimethylsulfoxide and stored at -196 degrees C until transfused. Sixteen dogs were irradiated with 800 rads and were supported with antibiotics and transfusions of irradiated homologous blood. They were transfused with the frozen and thawed buffy coat cells, and, if they survived, they were followed for 100 days, sacrificed, and their tissues studied. The mean yield of mononuclear cells during leukocytapheresis ranged from 4.1 +/- 2.0 X 10(9) (mean +/- SD) to 6.0 +/- 4.0 X 10(9) for the three leukacytapheresis methods; one technique was not as satisfactory as the other two. Six of the 16 dogs fully recovered with evidence of marrow rescue; however, only one had a dose of mononuclear cells less than 11.1 X 10(9). These data indicate that seven to 17 leukacytapheresis procedures would be required to reconstitute a 70 kilogram patient. These preliminary findings suggest that, because the yields of transplantable cells with current technology are not adequate, the transplantation potential of buffy coat cells exposed to mobilizing agents should be evaluated.

Animals↗
PubMedDate not supplied

Transforming growth factor-alpha secretion by epidermal growth factor-dependent human tumor cell lines.

Pairs of cell lines from spontaneous human tumors (cervical adenocarcinoma, melanoma, and synovial sarcoma) were established using serum-free culture conditions with and without exogenous epidermal growth factor (EGF). EGF-adapted cultures of melanoma and cervical adenocarcinoma origin secreted higher levels of bioactive transforming growth factor alpha (TGF-alpha) when compared to cultures maintained in the absence of EGF. Depletion of EGF for these EGF-adapted cultures resulted in growth arrest. In contrast, the sarcoma cell lines did not secrete TGF-alpha regardless of the culture conditions but EGF significantly stimulated proliferation of these cells in short-term assays. We show that exogenous EGF induces TGF-alpha production and supports proliferation of tumor cells of various tissue origin but is not essential for in vitro growth factor-deprived conditions.

Carcinoma↗
PubMedDate not supplied

An improved cytogenetic technique for human solid tumors grown in adhesive-tumor-cell culture system.

An improved technique for cytogenetic analysis of primary human solid tumors has been developed using an adhesive-tumor-cell culture system. While the previously described in situ harvesting procedure yielded highly condensed chromosome morphology and inadequate metaphase spread, the newly described harvesting procedures have yielded superior quality metaphase morphology and banding patterns. Cytogenetic analysis was successfully carried out on ten primary lung tumors and eight nonmalignant "normal" lung tissues. This procedure is now routinely used in this laboratory for other solid tumor cytogenetic analysis.

Cell Adhesion↗
PubMedDate not supplied

Early pulmonary toxicity after administration of high-dose BCNU.

Patients with solid tumor malignancies who failed extensive front-line treatments were treated with high-dose BCNU followed by autologous bone marrow transplantation. Since 1976, 14 patients were treated in this program with BCNU doses ranging from 600 to 1500 mg/m2 over 2 days. Three patients developed pulmonary toxicity only a few weeks after receiving high-dose BCNU at total doses of 900, 1000, and 1500 mg/m2. Two of the three patients had had prior irradiation to the primary tumor. The third patient did not have prior irradiation to the chest but had received prior nitrosourea therapy. The use of high-dose BCNU in transplantation may be limited to early pulmonary toxicity.

Adenocarcinoma↗
PubMedDate not supplied

Combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia.

The combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue was evaluated in the treatment of relapsed leukemia refractory to normal-dose chemotherapy. Cyclophosphamide was given at a total dose of 4.5 g/m2, BCNU at a dose of 300 mg/m2, and VP-16-213 at a dose of 600 mg/m2. Seven high-dose treatments followed by marrow rescue were administered to six patients. Two patients achieved complete remissions, three had partial remissions, and one achieved a minimal response. The toxicity of this regimen was moderate.

Acute Disease↗